London, UK, 17 May 2007: BioProgress plc (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, today announces the acquisition, subject to completion on 18 May 2007, of Rocgel™, an antacid used in the treatment of pain associated with gastro-intestinal conditions. The product, which is being acquired for EUR7.85 million, will add to the portfolio of the Company's sales and marketing division in France, Dexo S.A.
